This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Jan. 8, 2013 /PRNewswire/ -- Morgan & Morgan is investigating potential claims against the board of directors of Epocrates, Inc. (NASDAQ: EPOC) related to the proposed acquisition of Epocrates by Athenahealth. The transaction values Epocrates at approximately
$293 million or
$11.75 per share.
If you are a current shareholder of Epocrates and are interested in learning more about our
Epocrates merger investigation please contact
George Pressly, Esq. at 1 (800) 631-6234 or email George at
Our investigation concerns whether Epocrates's board of directors has breached its fiduciary duties to act in the best interests of all of the Epocrates shareholders and to take all necessary steps to ensure that Epocrates shareholders receive the maximum value readily available for their shares of EPOC common stock. This includes an examination of whether the board of directors properly shopped Epocrates before entering into this transaction, whether all material terms of the agreement have been properly disclosed to shareholders and whether
$11.75 is a fair price.
About Morgan & MorganMorgan & Morgan is one of the nation's largest 200 law firms. In addition to securities fraud, the firm also practices in the areas of antitrust, personal injury, consumer protection, overtime, and product liability. All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people." Investors may also follow us on Facebook at
Attorney advertising. Prior results do not guarantee a similar outcome.
Contact:Morgan & Morgan
Peter Safirstein, Esq.28 West 44th Street
New York, NY 100361-800-631-6234
SOURCE Morgan & Morgan